Annual Total Liabilities
$97.79 M
-$27.53 M-21.97%
December 31, 2023
Summary
- As of February 7, 2025, TSHA annual total liabilities is $97.79 million, with the most recent change of -$27.53 million (-21.97%) on December 31, 2023.
- During the last 3 years, TSHA annual total liabilities has risen by +$90.22 million (+1190.33%).
- TSHA annual total liabilities is now -21.97% below its all-time high of $125.33 million, reached on December 31, 2022.
Performance
TSHA Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Total Liabilities
$91.42 M
-$105.00 K-0.11%
September 30, 2024
Summary
- As of February 7, 2025, TSHA quarterly total liabilities is $91.42 million, with the most recent change of -$105.00 thousand (-0.11%) on September 30, 2024.
- Over the past year, TSHA quarterly total liabilities has dropped by -$153.46 million (-62.67%).
- TSHA quarterly total liabilities is now -62.67% below its all-time high of $244.88 million, reached on September 30, 2023.
Performance
TSHA Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
TSHA Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -22.0% | -62.7% |
| 3 y3 years | +1190.3% | -9.2% |
| 5 y5 years | +10000.0% | - |
TSHA Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -22.0% | at low | -62.7% | at low |
| 5 y | 5-year | -22.0% | >+9999.0% | -62.7% | +1106.2% |
| alltime | all time | -22.0% | >+9999.0% | -62.7% | +1106.2% |
Taysha Gene Therapies Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2024 | - | $91.42 M(-0.1%) |
| Jun 2024 | - | $91.53 M(-7.7%) |
| Mar 2024 | - | $99.15 M(+1.4%) |
| Dec 2023 | $97.79 M(-22.0%) | $97.79 M(-60.1%) |
| Sep 2023 | - | $244.88 M(+106.4%) |
| Jun 2023 | - | $118.66 M(+1.8%) |
| Mar 2023 | - | $116.55 M(-7.0%) |
| Dec 2022 | $125.33 M | $125.33 M(+24.9%) |
| Sep 2022 | - | $100.34 M(-8.5%) |
| Jun 2022 | - | $109.62 M(-4.9%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2022 | - | $115.25 M(-2.8%) |
| Dec 2021 | $118.57 M(+1464.5%) | $118.57 M(+17.8%) |
| Sep 2021 | - | $100.65 M(+81.8%) |
| Jun 2021 | - | $55.37 M(+177.4%) |
| Mar 2021 | - | $19.96 M(+163.3%) |
| Dec 2020 | $7.58 M(+4952.7%) | - |
| Dec 2020 | - | $7.58 M(-34.8%) |
| Sep 2020 | - | $11.62 M(-42.1%) |
| Jun 2020 | - | $20.09 M |
| Dec 2019 | $150.00 K | - |
FAQ
- What is Taysha Gene Therapies annual total liabilities?
- What is the all time high annual total liabilities for Taysha Gene Therapies?
- What is Taysha Gene Therapies annual total liabilities year-on-year change?
- What is Taysha Gene Therapies quarterly total liabilities?
- What is the all time high quarterly total liabilities for Taysha Gene Therapies?
- What is Taysha Gene Therapies quarterly total liabilities year-on-year change?
What is Taysha Gene Therapies annual total liabilities?
The current annual total liabilities of TSHA is $97.79 M
What is the all time high annual total liabilities for Taysha Gene Therapies?
Taysha Gene Therapies all-time high annual total liabilities is $125.33 M
What is Taysha Gene Therapies annual total liabilities year-on-year change?
Over the past year, TSHA annual total liabilities has changed by -$27.53 M (-21.97%)
What is Taysha Gene Therapies quarterly total liabilities?
The current quarterly total liabilities of TSHA is $91.42 M
What is the all time high quarterly total liabilities for Taysha Gene Therapies?
Taysha Gene Therapies all-time high quarterly total liabilities is $244.88 M
What is Taysha Gene Therapies quarterly total liabilities year-on-year change?
Over the past year, TSHA quarterly total liabilities has changed by -$153.46 M (-62.67%)